Relacorilant Plus Nab-Paclitaxel Improves Outcomes in Platinum-Resistant Ovarian Cancer: Brian Slomovitz, MD

Rákkutatás · Ovarian cancer

Relacorilant combined with nab‑paclitaxel significantly improved progression‑free and overall survival in patients with platinum‑resistant ovarian cancer in the phase 3 ROSELLA trial

Relacorilant combined with nab‑paclitaxel (Abraxane) significantly improved progression‑free and overall survival in patients with platinum‑resistant ovarian cancer in the phase 3 ROSELLA trial, according to Brian Slomovitz, MD, one of the investigators.

These data suggest that the addition of relacorilant to nab‑paclitaxel may provide a clinically meaningful benefit for patients with platinum‑resistant ovarian cancer, a setting with limited therapeutic options and poor prognosis.

Bizonyítékszint: Feltételezés / hírjelzés. Nincs önálló tudományos bizonyíték.

Eredeti forrás

Kapcsolódó jelek